All In Biotech

BLA 103132 · Schering

Intron A

Interferon Alfa-2b

Novel

Last checked: Nov 20, 2026Latest source record: Nov 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Jun 4, 1986

Approved uses

8

Original approval plus efficacy supplements

Registered trials

395

118 Phase 3, 10 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 21, 2001 Supplement 1144 · Efficacy
  • Aug 18, 1998 Supplement 1127 · Efficacy
  • Nov 6, 1997 Supplement 1116 · Efficacy · priority review ReviewLetterLabel
  • Mar 26, 1997 Supplement 1107 · Efficacy
  • Dec 5, 1995 Supplement 1096 · Efficacy
  • May 14, 1993 Supplement 1040 · Efficacy
  • Jul 13, 1992 Supplement 1030 · Efficacy
  • Jun 4, 1986 Original approval · Type 1 - New Molecular Entity Review
3 products under this application
  • INTRON A · INTERFERON ALFA-2B 25MIU/VIAL · VIAL, · Prescription
  • INTRON A · INTERFERON ALFA-2B 10MIU/VIAL · VIAL, · Prescription
  • INTRON A · INTERFERON ALFA-2B 18MIU/VIAL · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Interferon Alfa-2b" as an intervention, any sponsor and status, largest first.

All 395 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 412 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.